Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonidine SCHEMBL10972183 | 1.00 | ADRA2A (0.36) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL1172959 | 1.00 | ADRA2A (0.36) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL3974275 | 1.00 | ADRA2A (0.36) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL1369983 | 0.98 | MAPT (0.36) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL5982 | 0.98 | MAPT (0.36) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL9838987 | 0.96 | MAPT (0.35) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL22127030 | 0.96 | MAPT (0.35) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL22127029 | 0.94 | MAPT (0.34) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL1369066 | 0.94 | MAPT (0.34) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Clonidine SCHEMBL27404261 | 0.92 | MAPT (0.37) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7551 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576032-B2 | Liquid clonidine extended release composition | TRIS PHARMA, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260007638-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | AZURITY PHARMACEUTICALS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-12440474-B2 | Stable pharmaceutical compositions of clonidine | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| WO-2025203052-A1 | A STABLE ORAL LIQUID PHARMACEUTICAL FORMULATION OF CLONIDINE | WOCKHARDT LIMITED (IN) | 2025-10-02 | — | — | WO | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250195444-A1 | POLYMER-COATED NANOPARTICLES AND PREPARATION METHOD THEREFOR | SCINDY PHARMACEUTICAL (SUZHOU) CO., LTD (CN) | 2025-06-19 | — | — | US | claimed |
| US-20250152558-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | SLAYBACK PHARMA LLC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4551194-A2 | MULTILAMELLAR VESICLE DRUG FORMULATION | Nanostar Pharmaceuticals Ltd. (CA) | 2025-05-14 | — | — | EP | claimed |
| US-20250090602-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-4946848-A | Method of treating pruritus with nalmefene and clonidine | BAKER CUMINS DERMATOLOGICALS, INC. (US) | 1990-08-07 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4788189-A | Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking | GLAZER HOWARD I (US) | 1988-11-29 | — | — | US | claimed |
| US-4765974-A | Preparation for percutaneous administration | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1988-08-23 | — | — | US | claimed |
| US-4588739-A | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 1986-05-13 | — | — | US | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |
| US-4361564-A | Renoprotective treatments employing vasodilator compounds | EDWARDS K DAVID G | 1982-11-30 | — | — | US | claimed |